

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

RECEIVED.
SECRETARY OF THE
05 AUG -4 PM

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name Ricchetti Incorporated			
2. Address <input type="checkbox"/> Check if different than previously reported 1001 G Street NW Suite 600 East Washington DC 20001 US			
3. Principal place of business (if different than line 2) City State/Zip or Country			
4a. Contact Name Mr. James Heimbach	b. Telephone number 202-879-9367	c. E-mail jay@ricchettiinc.com	5. Senate ID # 62778-2
7. Client Name <input type="checkbox"/> Self Novartis	6. House ID # 3539501		

TYPE OF REPORT 8. Year 2005 Midyear (January 1-June 30) OR Year End (July 1-December 31)


9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying Act

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>60,000</u></p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____</p> <p>14. REPORTING METHOD. Check box to indicate exp accounting method. See instructions for description of op</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(1) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e)(1)(B) Internal Revenue Code</p>
--	--

Edit >

Signature  Date 8/4/05

Printed Name and Title James Heimbach, Vice President

Registrant Name Ricchetti Incorporated Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each co** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

Issues pertaining to the importation of prescription drugs, including:
 S. 334, the Pharamceutical Market Access and Drug Safety Act of 2005
 S. 184, the Safe Import Act of 2005
 S. 109, the Pharmaceutical Market Access Act of 2005
 HR 1626, the Medicare Prescription Drug Improvement Act
 Issues relating to the regulation of Plano contact lenses, including S 172

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. Senate
 U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

	Name	Covered Official Position (if applicable)
Steve	Ricchetti	
Jeff	Ricchetti	
Lisa	Kountoupes	
Luke	Albee	Chief of Staff to Senator Patrick Leahy (VT)
James	Heimbach	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis is owned by Novartis AG, Basel, Switzerland

Signature

Date

Printed Name and Title James Heimbach, Vice President

LD-2DS (REV. 4/03)

Page 2

Registrant Name Ricchetti Incorporated Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which th engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each co** information as requested. Attach additional page(s) as needed.

15. General issue area code ADV - Advertising (one per page)

16. Specific lobbying issues

Issues pertaining to the direct-to-consumer advertising of prescription drugs

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. Senate
U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

	Name	Covered Official Position (if applicable)
Steve	Ricchetti	
Jeff	Ricchetti	
Lisa	Kountoupes	
Luke	Albee	Chief of Staff to Senator Patrick Leahy (VT)
James	Heimbach	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis is owned by Novartis AG, Basel, Switzerland

Registrant Name Ricchetti Incorporated Client Name Novartis

LOBBYINGACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

Issues pertaining to the implementation of the Medicare Modernization Act, specifically issues relating to prescription drug discount cards

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. Senate
U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

	Name	Covered Official Position (if applicable)
Steve	Ricchetti	
Jeff	Ricchetti	
Lisa	Kountoupes	
Luke	Albee	Chief of Staff to Senator Patrick Leahy (VT)
James	Heimbach	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis is owned by Novartis AG, Basel, Switzerland

Printed Name and Title James Heimbach, Vice President

LD-2DS (REV. 4/03)

Page 4

Registrant Name Ricchetti Incorporated Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code PHA - Pharmacy (one per page)

16. Specific lobbying issues

Issues relating to the regulation of the sale of pharmaceuticals, including work on:
 S. 103, the Combat Meth Act of 2005

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. Senate
 U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

	Name	Covered Official Position (if applicable)
Steve	Ricchetti	
Jeff	Ricchetti	
Lisa	Kountoupes	
Luke	Albee	Chief of Staff to Senator Patrick Leahy (VT)
James	Heimbach	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis is owned by Novartis AG, Basel, Switzerland

Printed Name and Title James Heimbach, Vice President

LD-2DS (REV. 4/03)

Page 5

Registrant Name Ricchetti Incorporated

Client Name Novartis

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

City

State/Zip

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

Lisa

Kountoupes

ISSUE UPDATE

24. General lobbying issues that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal place of Business (city and state or country)


26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	On behalf of client

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant affiliated organization

Signature 

Date 8/4/05

